2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4509 Real-world outcomes of lisocabtagene maraleucel (liso-cel) for patients (pts) with second-line (2L) relapsed or refractory (R/R) large B-cell lymphoma (LBCL): 2-y follow-up from the center for international blood and marrow transplant research (CIBMTR) registry

Bradley Hunter, MD, MPH, Krish Patel, MD2, Alexander P. Boardman, MD3, Ogechukwu Egini4, Matthew Frigault, MD5, Matthew A. Lunning, DO, FACP6, Jordan Gauthier, MD7, Tara Graff, DO, MS8, Manali Kamdar, MD9, Samantha Jaglowski10, Tiening Chen, MS11, Jinalben Patel, MPH, BDS12, Maria Bobillo, MD13, Alex Francisco Herrera, MD14, Catherine J Lee, MD, MS15, Dasom (Caroline) Lee, MD16, Mazyar Shadman, MD, MPH17, Swetha Thiruvengadam, MD18, David Bernasconi19, Maria Strocchia20, Farah Toron21, Sairah Ahmed, MD22, Jennifer L. Crombie23, Saurabh Dahiya, MD, FACP24
1 Intermountain LDS Hospital, Salt Lake City, Utah, United States
2 Sarah Cannon Research Institute, Nashville, Tennessee, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Rutgers Cancer Institute, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
5 Massachusetts General Hospital, Boston, Massachusetts, United States
6 University of Nebraska Medical Center, Omaha, Nebraska, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States
8 Mission Cancer and Blood/UIHSMG, Des Moines, Iowa, United States
9 University of Colorado Cancer Center, Aurora, Colorado, United States
10 Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, Wisconsin, United States
11 Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, Wisconsin, United States
12 Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin, Milwaukee, Wisconsin, United States
13 University of Utah School of Medicine, Salt Lake City, Utah, United States
14 City of Hope, Duarte, California, United States
15 Fred Hutchinson Cancer Center, Seattle, Washington, United States
16 Stanford University School of Medicine, Palo Alto, California, United States
17 Fred Hutchinson Cancer Center, Seattle, Washington, United States
18 Duarte Cancer Center, City of Hope Medical Center, Duarte, California, United States
19 Bristol Myers Squibb, Boudry, Switzerland
20 Bristol Myers Squibb, Boudry, Switzerland
21 Bristol Myers Squibb, Uxbridge, United Kingdom
22 MD Anderson Cancer Center, Houston, Texas, United States
23 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
24 Stanford University, Stanford, California, United States

Introduction: In the pivotal TRANSFORM study (NCT03575351), liso-cel demonstrated superior efficacy over standard of care as 2L treatment (tx) in pts with R/R LBCL, with durable responses and manageable safety. Real-world analyses using data from CIBMTR reinforced the clinically meaningful outcomes of liso-cel in routine practice among pts with 2L or later R/R LBCL (Odstrcil Bobillo et al. Blood 2024; Crombie et al. Blood 2026). Continued follow-up is needed to characterize the long-term durability of response and clinical benefit with liso-cel in this setting. Here, we report effectiveness and safety outcomes for liso-cel among pts with 2L R/R LBCL after approximately 2 y of follow-up based on data collected in the CIBMTR Registry.

Methods: This observational study included pts in the United States with 2L R/R LBCL who received commercial liso-cel (07/2022‒08/2024) and had ≥1 postinfusion assessment for effectiveness and safety reported to CIBMTR. Effectiveness outcomes were ORR, CR rate, duration of response (DOR), PFS, and OS; subgroup analyses stratified pts by TRANSFORM eligibility status (ineligible vs eligible/unknown), disease status at infusion (refractory vs early relapse [within 12 mo of 1L tx]), and age (<65 vs ≥65 y). With extended follow-up, safety outcomes of interest included clinically significant infections (any infection requiring tx), second primary malignancies (SPMs), nonrelapse mortality (NRM), and deaths.

Results: Of 199 pts, 58% were male; median age was 72 y (range, 27‒87; <65 y, 23%; ≥65 y, 77%). At infusion, 53% of pts had refractory disease and 46% had early relapsed disease; 70% would have been ineligible for TRANSFORM primarily due to age and/or comorbidity burden (eligible/unknown, 30%). The most common LBCL subtypes were DLBCL (84%) and high-grade B-cell lymphoma (12%). Among pts with available data, elevated LDH was reported in 43% (82/190); 94% (184/195) had ECOG PS 0‒1 and 64% (101/157) had ≥1 comorbidity, the most common being cardiac (31%), pulmonary (20%), and obesity (14%). Most pts (73%) received bridging therapy.

At a median follow-up of 23.7 mo (95% CI, 22.1‒24.1), ORR was 83% (95% CI, 77‒88) with a CR rate of 74% (95% CI, 68‒80). Median DOR and OS were not reached (NR); median PFS was 12.9 mo (95% CI, 8.2‒NR). Estimated probabilities (95% CI) of DOR, PFS, and OS at 24 mo were 56% (47‒64), 45% (38‒52.5), and 57% (49‒64), respectively. For the 147 pts who achieved CR, 24-mo DOR, PFS, and OS rates (95% CI) were 60% (51‒68), 59% (50‒67), and 73% (63‒80), respectively.

Effectiveness outcomes across subgroups were generally consistent with the overall population. Among the TRANSFORM-ineligible population, 24-mo DOR, PFS, and OS rates (95% CI) were 52% (42‒61), 42% (34‒51), and 53% (43‒61), respectively, compared with 65% (48‒77), 53% (38.5‒65), and 68% (53.5‒78.5), respectively, in the eligible/unknown population. For pts with refractory vs early relapsed disease, 24-mo DOR, PFS, and OS rates (95% CI) were 48.5% (36‒60) vs 64% (51‒74), 39% (29‒49) vs 52% (41‒62), and 49% (38‒60) vs 65% (54‒74), respectively. When stratified by age, 24-mo DOR, PFS, and OS rates (95% CI) were 69% (52‒81), 63% (47‒76), and 76% (60‒86), respectively, in younger pts (<65 y) and 51% (40‒60), 40% (31‒48), and 51% (42‒59.5), respectively, among those aged ≥65 y.

No new safety signals were observed, and the safety profile of liso-cel was generally similar to prior analyses with shorter follow-up. Clinically significant infections were reported in 44% of pts; bacterial (24%) and viral (24%) infections occurred most frequently. Overall, 19% of pts experienced infections within 100 days after infusion, and rates generally decreased over time; incidence from 1 to 2 y postinfusion was 4.8 cases per 100 pt-mo (95% CI, 3.5‒6.5). The SPM rate was 9%. A total of 79 deaths were reported, with disease persistence/progression as the most common cause (24%). At 24 mo, the NRM rate was 8% (95% CI, 5‒13) and cumulative incidence of relapse or progression was 46.5% (95% CI, 39‒53.5) based on 90 events.

Conclusions: In this real-world study of a broad population of pts with 2L R/R LBCL, 57% were still alive and 45% remained progression-free, with no new safety signals observed after approximately 2 y of follow-up. The durable outcomes observed in the overall cohort and across key pt subgroups reinforce the robust and sustained clinical benefit of liso-cel, further supporting its role as a standard of care tx in 2L R/R LBCL.

Bradley Hunter, MD, MPH: Caribou Biosciences - Honoraria; Poseida Therapeutics - Honoraria; Kite - Honoraria; BMS - Honoraria; Kyverna (paid to institution) - Honoraria; Johnson & Johnson - Honoraria; Novartis - Honoraria; Johnson & Johnson - Research Funding; BMS - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); Kyverna - Consultancy (Includes expert testimony); Caribou Biosciences - Consultancy (Includes expert testimony); Poseida Therapeutics - Consultancy (Includes expert testimony)